Understanding the biology of low-risk prostate cancer
Defining the Biological Arc of Grade Group 1 Prostate Cancer
['FUNDING_R37'] · UNIVERSITY OF MICHIGAN AT ANN ARBOR · NIH-10897021
This study is looking at Grade Group 1 prostate cancer to see how it behaves over time and whether it has any similarities to more aggressive types, especially in African American men, so we can better understand what might indicate a need for more treatment.
Quick facts
| Phase | ['FUNDING_R37'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF MICHIGAN AT ANN ARBOR (nih funded) |
| Locations | 1 site (ANN ARBOR, UNITED STATES) |
| Trial ID | NIH-10897021 on ClinicalTrials.gov |
What this research studies
This research aims to clarify the biological behavior of Grade Group 1 prostate cancer, which is often monitored rather than treated immediately. The study will investigate whether this type of cancer progresses over time and if it shares molecular characteristics with more aggressive forms of prostate cancer. By analyzing tissue samples and molecular features, the research seeks to identify any indicators that could predict the presence of higher-grade cancer in patients. This work is particularly focused on understanding how these factors may differ in African American men.
Who could benefit from this research
Good fit: Ideal candidates for this research include men diagnosed with Grade Group 1 prostate cancer, particularly those who are African American.
Not a fit: Patients with higher-grade prostate cancer or those not diagnosed with prostate cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more accurate monitoring strategies for patients with low-risk prostate cancer, potentially reducing unnecessary treatments.
How similar studies have performed: Previous research has shown promise in understanding the biological behavior of prostate cancer, but this specific focus on Grade Group 1 and its implications for African American men is relatively novel.
Where this research is happening
ANN ARBOR, UNITED STATES
- UNIVERSITY OF MICHIGAN AT ANN ARBOR — ANN ARBOR, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: SALAMI, SIMPA SAMUEL — UNIVERSITY OF MICHIGAN AT ANN ARBOR
- Study coordinator: SALAMI, SIMPA SAMUEL
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.